Faes Farma (FAE.MC) Akcija Цена
Faes Farma Цена
U poslednjih 19 godina prihod Faes Farma rastao je 6,5 % godišnje i dostigao 610,46 М EUR. Zarada po akciji rasla je 2,9 % godišnje u poslednjih 19 godina. Za Faes Farma neto marža od 13,0 % je pala u odnosu na 20,7 % pre nekoliko godina. Po današnjoj ceni dividendni prinos iznosi otprilike 3,66 %. Odnos isplate je oko 70 % dobiti. Dividenda je rasla 5,5 % godišnje u poslednjih 19 godina. Konsenzusna 12-mesečna ciljana cena za Faes Farma je 5,61 EUR, oko iznad kurs za 14,6 %. Od 10 analitičara 6 preporučuje kupovinu — ukupni konsenzus je Kupi.
Cena akcije Faes Farma
Pristupite ovim podacima preko Eulerpool API-ja
100.000 zahteva/mes. besplatno · bez kartice
Faes Farma poslovni model i analiza akcije
Često postavljana pitanja o akciji Faes Farma
The business model of Faes Farma SA is focused on the research, development, manufacture, and commercialization of pharmaceutical products. The company specializes in the areas of prescription drugs, hospital medications, and non-prescription drugs. Faes Farma SA operates through a diversified portfolio, catering to various therapeutic areas such as respiratory, dermatology, allergy, and gastrointestinal disorders. The company aims to provide innovative and effective solutions to improve people's health and quality of life. Faes Farma SA's commitment to scientific excellence, strategic partnerships, and continuous product development enables it to meet the evolving needs of patients worldwide.
Faes Farma SA is primarily active in the pharmaceutical industry.
Some of the main competitors of Faes Farma SA in the market include pharmaceutical companies like Grupo Ferrer Internacional, Laboratorios Rubió, Almirall, and Laboratorios Normon.
Faes Farma SA is a leading pharmaceutical company with a rich history and strong background. Established in 1933, Faes Farma has grown steadily over the years to become a key player in the healthcare industry. The company specializes in the research, development, manufacturing, and commercialization of innovative drugs and health products. With a primary focus on respiratory, allergy, and anti-inflammatory treatments, Faes Farma has built a solid reputation for delivering high-quality and effective pharmaceutical solutions. Through continuous innovation and strategic partnerships, the company has successfully expanded its global presence and has become a trusted name in the pharmaceutical sector.
Faes Farma SA, a leading pharmaceutical company, has achieved several significant milestones throughout its history. One notable milestone is the successful development and commercialization of innovative pharmaceutical products. The company has also expanded its market reach globally, establishing a strong presence in various countries. Furthermore, Faes Farma SA has demonstrated continuous growth through strategic partnerships, collaborations, and acquisitions. These milestones reflect the company's commitment to advancing healthcare and delivering quality solutions to customers worldwide. With its relentless dedication and industry expertise, Faes Farma SA has emerged as a prominent player in the pharmaceutical sector, consistently achieving commendable results.
Faes Farma SA is primarily present in Spain and Portugal.
Faes Farma SA represents values and a corporate philosophy centered on innovation, excellence, and commitment to improving healthcare. With a focus on research and development, the company strives to develop high-quality pharmaceutical products that address unmet medical needs. With a long history dating back to 1933, Faes Farma SA emphasizes ethical business practices and sustainable growth. By leveraging its scientific expertise and state-of-the-art technologies, the company aims to provide effective therapies and contribute to the well-being of patients worldwide. Faes Farma SA's dedication to innovation and patient-centric approach makes it a reputable player in the pharmaceutical industry.
Analitičari trenutno postavljaju prosečnu ciljanu cenu 5,36 EUR za akciju Faes Farma (medijana: 5,61 EUR), što znači +10,9 % u odnosu na poslednju cenu. Konsenzus se zasniva na 10 ocena.
10 analitičara trenutno ocenjuje akciju Faes Farma: 6 preporučuje kupovinu, 3 držanje i 1 prodaju. Za 2026 analitičari očekuju da Faes Farma ostvari prihod 737,52 М EUR i zaradu po akciji 0,29 EUR.
Akcija Faes Farma (FAE.MC) kotira na 7 berze, uključujući: London (0K9H.L), Frankfurt (FFEA.F), München (FFEA.MU), Düsseldorf (FFEA.DU), Madrid (FAE.MC).
Faes Farma SA is a leading pharmaceutical company specializing in the manufacturing and marketing of medicines and medical products. The company was founded in 1933 and is headquartered in Barcelona, Spain. Faes Farma operates in various business areas, including pharmaceutical products, diagnostic and laboratory services, and skincare products. Pharmaceutical products Faes Farma offers a wide range of pharmaceutical products that can be used to treat various diseases and ailments. The company focuses on the development of drugs in the areas of pain medicine, allergology, and respiratory and eye diseases. One outstanding product is Bilastine, an antihistamine used to treat allergic diseases. In 2020, the company generated sales of €136 million with Bilastine. Diagnostic and laboratory services Faes Farma also operates a division for diagnostic and laboratory services. The company offers various tests to detect and treat diseases early. For example, Faes Farma offers a test to determine if a person is suffering from celiac disease. Another example is a test that detects the presence of antibodies against SARS-CoV-2. Skincare products The company also offers a line of skincare products marketed under the brand Bionike. These products have been specifically developed for people with sensitive skin and do not contain questionable ingredients. The product range includes face creams, cleansers, and sunscreens. Faes Farma has a diversified business model based on the development of new products and the expansion into new markets. The company is focused on innovation and invests a significant portion of its sales in research and development every year. Thanks to its innovative capacity and strong market presence, Faes Farma has experienced solid growth in recent years. In 2020, the company had sales of €317.2 million. The size of the company allows for international business expansion. Faes Farma operates in over 80 countries and has a strong presence, particularly in Latin America and Asia.
očekivana prihod od Faes Farma je 737,52 М EUR. Ova cifra je zasnovana na trenutnim finansijskim podacima i odražava poslovne rezultate preduzeća.
očekivana dobit od Faes Farma je 89,05 М EUR. Neto dobit pokazuje profitabilnost preduzeća nakon odbitka svih troškova.
Odnos cene i zarade (KGV) za Faes Farma je trenutno 17,11. KGV poredi sadašnju cenu akcije sa zaradom po akciji i pomaže investitorima da procene valuaciju akcije Faes Farma.
Odnos cene i prihoda (KUV) za Faes Farma je trenutno 2,07. KUV poredi tržišnu kapitalizaciju sa godišnjim prihodima i služi kao metrika valuacije za akciju Faes Farma.
Eulpool score kvaliteta za Faes Farma je 7/10.
ISIN za Faes Farma je ES0134950F36. ISIN (International Securities Identification Number) je globalno jedinstveni identifikator za hartije od vrednosti.
WKN za Faes Farma je A0MKAC. WKN (Wertpapierkennnummer) je šestocifreni nemački broj za identifikaciju hartija od vrednosti.
Ticker za Faes Farma je FAE.MC. Simbol tikera se koristi za trgovinu akcijama Faes Farma na berzanskom tržištu.
Faes Farma акција
Faes Farma Peer grupa
Faes Farma Тикер
Faes Farma FIGI
Sve ključne metrke i detaljne analize Faes Farma u dubinskoj analizi
Naša analiza akcija za akciju Faes Farma uključuje važne finansijske pokazatelje kao što su prihod, profit, P/E odnos, P/S odnos, EBIT, kao i informacije o dividendama. Takođe, razmatramo aspekte poput akcija, tržišne kapitalizacije, dugova, kapitala i obaveza kompanije Faes Farma. Ako tražite detaljnije informacije o ovim temama, na našim podstranicama vam nudimo opsežne analize: